Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22
- PMID: 3472585
- PMCID: PMC1386095
- DOI: 10.1111/j.1365-2125.1987.tb03075.x
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22
Abstract
In order to determine on which chromosome the gene controlling human cytochrome P-450 (debrisoquine/sparteine type) is located a linkage study of polymorphic sparteine oxidation (PSO) to various polymorphic markers was carried out. Positive information for linkage between PSO and the P1 blood group was obtained with a maximal LOD-score of LOD = 3.35 for both male and female recombination fraction estimates of theta m = theta f = 0.0. The P1 blood group has been recently mapped to the long arm of chromosome 22. Thus it can be concluded that the gene controlling human cytochrome P-450 (debrisoquine/sparteine) is situated on the long arm of chromosome 22 in close vicinity to P1.
Similar articles
-
Polymorphic oxidation of debrisoquine and sparteine.Prog Clin Biol Res. 1986;214:157-67. Prog Clin Biol Res. 1986. PMID: 3523506 Review. No abstract available.
-
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.Am J Hum Genet. 1991 May;48(5):943-50. Am J Hum Genet. 1991. PMID: 1673290 Free PMC article.
-
Molecular genetics of the debrisoquin-sparteine polymorphism.Clin Pharmacol Ther. 1991 Sep;50(3):233-8. doi: 10.1038/clpt.1991.131. Clin Pharmacol Ther. 1991. PMID: 1680592 Review. No abstract available.
-
Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.Pharmacogenetics. 1992 Apr;2(2):89-92. doi: 10.1097/00008571-199204000-00006. Pharmacogenetics. 1992. PMID: 1302046
-
A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.Can J Physiol Pharmacol. 1984 Jul;62(7):860-2. doi: 10.1139/y84-144. Can J Physiol Pharmacol. 1984. PMID: 6498616
Cited by
-
Cytochrome P450 2D6.Pharmacogenet Genomics. 2009 Jul;19(7):559-62. doi: 10.1097/FPC.0b013e32832e0e97. Pharmacogenet Genomics. 2009. PMID: 19512959 Free PMC article. Review. No abstract available.
-
Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.Clin Pharmacokinet. 1990 Mar;18(3):220-39. doi: 10.2165/00003088-199018030-00004. Clin Pharmacokinet. 1990. PMID: 2182263 Review.
-
Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.Clin Investig. 1992 Mar-Apr;70(3-4):307-19. doi: 10.1007/BF00184667. Clin Investig. 1992. PMID: 1355678
-
DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.Hum Genet. 1993 Oct;92(4):367-72. doi: 10.1007/BF01247337. Hum Genet. 1993. PMID: 7901140
-
Genetic predisposition to lung cancer.Br J Cancer. 1990 Feb;61(2):195-206. doi: 10.1038/bjc.1990.37. Br J Cancer. 1990. PMID: 2178665 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources